Abstract

Introduction: Hepatitis C has been treated with interferon and ribavirin for over a decade with described global sustained virological response rates of 33% to 56%. Direct acting antiviral drugs available since 2013 in USA and 2015 in Brazil are changing this reality.

Purpose: Analyze the real-life efficacy and safety of interferon-free therapy

Methods: Repot six cases of different treatments guided by north-american and european guildelines.

Results: Every reported patient achieved sustained virological response. The only adverse event was anemia in one patient.

Conclusion: Direct-acting antiviral drugs will dramatically change the population which can be treated and increase sustained virological response rates.

Keywords: Brazil; Chronic hepatitis C; Direct antiviral therapy; HCV; Real World